Physician profile
Robert G Barone
NPI 1467486530
$1,908.94
in general payments reported to CMS, 2019-2025
15 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $136 · 2021: $27.35 · 2022: $157 · 2023: $518 · 2024: $398 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $648.36 | 2020-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $300.65 | 2023-2025 | Izervay |
| Abbvie INC. | $275.18 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $233.56 | 2019-2021 | |
| Alcon Vision LLC | $99.82 | 2019-2025 | Tryptyr, Eysuvis |
| Genentech USA, INC. | $75.29 | 2022-2023 | Lucentis, Vabysmo |
| Coopervision INC. | $66.01 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $54.18 | 2024-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $32.01 | 2022-2023 | Infuse |
| Oyster Point Pharma, INC. | $29.49 | 2022-2024 | Tyrvaya |
| Horizon Therapeutics Plc | $28.08 | 2023 | Tepezza |
| Genmab U.S., INC. | $18.81 | 2023 | Tivdak |
| Tarsus Pharmaceuticals, INC. | $17.91 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $15.00 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Barone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.